Latest Insider Transactions at Lumos Pharma, Inc. (LUMO)
This section provides a real-time view of insider transactions for Lumos Pharma, Inc. (LUMO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LUMOS PHARMA, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LUMOS PHARMA, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 25
2022
|
Joseph S Mc Cracken Director |
BUY
Open market or private purchase
|
Direct |
3,170
+21.29%
|
$25,360
$8.6 P/Share
|
|
Aug 02
2022
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,407
-12.16%
|
$27,256
$8.11 P/Share
|
|
Aug 01
2022
|
John C. Mc Kew Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,593
-5.38%
|
$12,744
$8.17 P/Share
|
|
Aug 01
2022
|
Lori D Lawley Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-2.21%
|
$1,832
$8.17 P/Share
|
|
Jun 06
2022
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
169
-0.58%
|
$1,183
$7.62 P/Share
|
|
Apr 05
2022
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,214
-7.03%
|
$17,712
$8.32 P/Share
|
|
Apr 01
2022
|
Richard J Hawkins Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,466
-0.2%
|
$13,194
$9.23 P/Share
|
|
Apr 01
2022
|
Lori D Lawley Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
274
-2.71%
|
$2,466
$9.23 P/Share
|
|
Apr 01
2022
|
John C. Mc Kew Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,036
-3.19%
|
$9,324
$9.23 P/Share
|
|
Apr 01
2022
|
Bradley J Powers General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-5.79%
|
$3,078
$9.23 P/Share
|
|
Feb 01
2022
|
Richard J Hawkins Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
173
-0.02%
|
$1,730
$10.02 P/Share
|
|
Feb 01
2022
|
Richard J Hawkins Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+0.6%
|
$45,000
$10.02 P/Share
|
|
Feb 01
2022
|
David B Karpf Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
400
+4.82%
|
$4,000
$10.02 P/Share
|
|
Feb 01
2022
|
Lori D Lawley Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
65
-0.64%
|
$650
$10.02 P/Share
|
|
Feb 01
2022
|
Lori D Lawley Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+8.94%
|
$10,000
$10.02 P/Share
|
|
Feb 01
2022
|
John C. Mc Kew Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
100
-0.31%
|
$1,000
$10.02 P/Share
|
|
Feb 01
2022
|
John C. Mc Kew Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,500
+4.4%
|
$15,000
$10.02 P/Share
|
|
Feb 01
2022
|
Bradley J Powers General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
78
-1.3%
|
$780
$10.02 P/Share
|
|
Feb 01
2022
|
Bradley J Powers General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
900
+13.08%
|
$9,000
$10.02 P/Share
|
|
Feb 01
2022
|
Aaron Schuchart Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
52
-1.29%
|
$520
$10.02 P/Share
|
|
Feb 01
2022
|
Aaron Schuchart Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+19.85%
|
$10,000
$10.02 P/Share
|
|
Sep 08
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+1.35%
|
$110,000
$11.21 P/Share
|
|
Sep 08
2021
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,214
-6.66%
|
$24,354
$11.3 P/Share
|
|
Sep 07
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+1.37%
|
$110,000
$11.11 P/Share
|
|
Sep 03
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
8,100
+1.13%
|
$89,100
$11.35 P/Share
|
|
Sep 02
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
6,300
+0.89%
|
$69,300
$11.23 P/Share
|
|
Sep 01
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
4,589
+0.66%
|
$45,890
$10.87 P/Share
|
|
Aug 31
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
6,000
+0.86%
|
$60,000
$10.7 P/Share
|
|
Aug 30
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
8,625
+1.24%
|
$86,250
$10.52 P/Share
|
|
Aug 27
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
4,981
+0.73%
|
$49,810
$10.5 P/Share
|
|
Aug 26
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
6,200
+0.91%
|
$62,000
$10.07 P/Share
|
|
Aug 25
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
14,900
+2.19%
|
$134,100
$9.87 P/Share
|
|
Aug 24
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
10,775
+1.63%
|
$96,975
$9.45 P/Share
|
|
Aug 23
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
37,800
+5.57%
|
$340,200
$9.58 P/Share
|
|
Aug 20
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
35,679
+5.58%
|
$285,432
$8.73 P/Share
|
|
Aug 19
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
20,000
+3.4%
|
$160,000
$8.45 P/Share
|
|
Aug 18
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
28,870
+5.01%
|
$230,960
$8.73 P/Share
|
|
Aug 17
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
16,000
+2.99%
|
$128,000
$8.47 P/Share
|
|
Aug 16
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
31,000
+5.81%
|
$217,000
$7.96 P/Share
|
|
Aug 13
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
31,000
+6.17%
|
$217,000
$7.86 P/Share
|
|
Aug 12
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
31,000
+6.57%
|
$217,000
$7.55 P/Share
|
|
Aug 12
2021
|
Aaron Schuchart Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
1,700
+35.89%
|
$11,900
$7.42 P/Share
|
|
Aug 11
2021
|
Joseph S Mc Cracken Director |
BUY
Open market or private purchase
|
Direct |
7,475
+46.64%
|
$52,325
$7.55 P/Share
|
|
Aug 11
2021
|
Aaron Schuchart Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
300
+18.33%
|
$2,100
$7.35 P/Share
|
|
Aug 01
2021
|
Lori D Lawley Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+28.99%
|
-
|
|
Aug 01
2021
|
John C. Mc Kew Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+37.58%
|
-
|
|
May 20
2021
|
Chad Allen Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+25.43%
|
-
|
|
May 20
2021
|
Kevin M. Lalande Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+25.43%
|
-
|
|
May 20
2021
|
Joseph S Mc Cracken Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+25.43%
|
-
|
|
May 20
2021
|
Thomas A. Raffin Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+4.26%
|
-
|